Ross Dunne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ross Dunne has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Declan Marcellino McLoughlin
Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
8 shared publications - Benjamin R. Underwood
Department of Psychiatry University of Cambridge Cambridge UK
3 shared publications - Iracema Leroi
Global Brain Health Institute, University of California San Francisco, Trinity College Dublin, San Francisco, CA, USA
3 shared publications Paresh Malhotra
Imperial College London
3 shared publicationsAdam Kavanagh
From the Department of Psychiatry, Trinity College Dublin, St. Patrick's University Hospital, Dublin, Ireland; Trinity College Institute of Neuroscience, Trinity College Dublin, Ireland; the Department of Psychology, University of Limerick, Castletroy, Co. Limerick, Ireland; and the Department of Biostatistics, Institute of Psychiatry, Psychology and Neuroscience, King's College London
2 shared publicationsAlistair Burns
Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK
2 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1
Interpreting Evolving Evidence in Alzheimer’s Disease: Implications for Dementia Clincians – CORRIGENDUM
- 21 September 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1
Open AccessInterpreting Evolving Evidence in Alzheimer’s Disease: Implications for Dementia Clincians – CORRIGENDUM
- Open Access
- 5 August 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-2
Interpreting evolving evidence in Alzheimer’s disease: implications for dementia clinicians
Interpreting evolving evidence in Alzheimer’s disease: implications for dementia clinicians
- 5 August 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-2
Open AccessInterpreting evolving evidence in Alzheimer’s disease: implications for dementia clinicians
Interpreting evolving evidence in Alzheimer’s disease: implications for dementia clinicians
- Open Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Safety of Testosterone Therapy in Chronic Kidney Disease: A Propensity Score-Matched Cohort Study
Merlino L, et al. World J Mens Health. 2026 ;44:e24. https://doi.org/10.5534/wjmh.250333
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Open AccessSafety of Testosterone Therapy in Chronic Kidney Disease: A Propensity Score-Matched Cohort Study
Merlino L, et al. World J Mens Health. 2026 ;44:e24. https://doi.org/10.5534/wjmh.250333
- 24 May 2024
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 224 (6) , 187-188
Shifting paradigms in dementia care: navigating new therapies and prevention strategies
- 24 May 2024
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 224 (6) , 187-188
Shifting paradigms in dementia care: navigating new therapies and prevention strategies
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Risk Reduction: A Novel Brain Health‐focused Pathway for Patients with Mild Cognitive Impairment in Greater Manchester
Background: Studies have indicated that addressing lifestyle risk factors in people with mild cognitive impairment (MCI), may slow symptom progression or even reduce their risk of progressing to dementia. However, this important window for dementia risk reduction and brain health promotion is often missed in existing UK clinical pathways. This work aims to develop and pilot a brain health navigation pathway for individuals receiving an MCI diagnosis from a UK memory assessment service in Greater Manchester.Methods: To date we have worked closely with people living with MCI to develop this pathway and all associated resources and materials. In January 2023 we developed and embedded a new role, which we refer to as a brain health navigator, within an existing memory assessment service team in one commissioning region of Greater Manchester. Starting in April 2023, patients identified in memory assessments as having MCI, will receive a referral to the brain health navigation service. With support from our navigator, all those who accept the referral will receive:• A personalised brain health plan.• Brain health and prevention information and signposting to local community and professional resources.• A follow‐up appointment to assess the impact of this intervention on their wellbeing, skills, knowledge, and confidence in managing their own health.Results: We will use a mixed methods approach to evaluate this work. We will collect Quantitative data describing the number of patients between April and June 2023 accepting a referral into the program, the number accessing community services; and wellbeing scores (using the Warwick‐Edinburgh Mental Wellbeing scale) pre‐and post‐intervention. Qualitative feedback will also be discussed including patient and clinical reflections of the service.Conclusions: Our poster will discuss the feasibility and effectiveness of this model of patient support and how this approach may be expanded across the UK and beyond.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open AccessRisk Reduction: A Novel Brain Health‐focused Pathway for Patients with Mild Cognitive Impairment in Greater Manchester
Background: Studies have indicated that addressing lifestyle risk factors in people with mild cognitive impairment (MCI), may slow symptom progression or even reduce their risk of progressing to dementia. However, this important window for dementia risk reduction and brain health promotion is often missed in existing UK clinical pathways. This work aims to develop and pilot a brain health navigation pathway for individuals receiving an MCI diagnosis from a UK memory assessment service in Greater Manchester.Methods: To date we have worked closely with people living with MCI to develop this pathway and all associated resources and materials. In January 2023 we developed and embedded a new role, which we refer to as a brain health navigator, within an existing memory assessment service team in one commissioning region of Greater Manchester. Starting in April 2023, patients identified in memory assessments as having MCI, will receive a referral to the brain health navigation service. With support from our navigator, all those who accept the referral will receive:• A personalised brain health plan.• Brain health and prevention information and signposting to local community and professional resources.• A follow‐up appointment to assess the impact of this intervention on their wellbeing, skills, knowledge, and confidence in managing their own health.Results: We will use a mixed methods approach to evaluate this work. We will collect Quantitative data describing the number of patients between April and June 2023 accepting a referral into the program, the number accessing community services; and wellbeing scores (using the Warwick‐Edinburgh Mental Wellbeing scale) pre‐and post‐intervention. Qualitative feedback will also be discussed including patient and clinical reflections of the service.Conclusions: Our poster will discuss the feasibility and effectiveness of this model of patient support and how this approach may be expanded across the UK and beyond.
- Open Access
- 17 November 2020
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 50 (1) , 72-80
Mild Cognitive Impairment: the Manchester consensus
Given considerable variation in diagnostic and therapeutic practice, there is a need for national guidance on the use of neuroimaging, fluid biomarkers, cognitive testing, follow-up and diagnostic terminology in mild cognitive impairment (MCI). MCI is a heterogenous clinical syndrome reflecting a change in cognitive function and deficits on neuropsychological testing but relatively intact activities of daily living. MCI is a risk state for further cognitive and functional decline with 5–15% of people developing dementia per year. However, ~50% remain stable at 5 years and in a minority, symptoms resolve over time. There is considerable debate about whether MCI is a useful clinical diagnosis, or whether the use of the term prevents proper inquiry (by history, examination and investigations) into underlying causes of cognitive symptoms, which can include prodromal neurodegenerative disease, other physical or psychiatric illness, or combinations thereof. Cognitive testing, neuroimaging and fluid biomarkers can improve the sensitivity and specificity of aetiological diagnosis, with growing evidence that these may also help guide prognosis. Diagnostic criteria allow for a diagnosis of Alzheimer’s disease to be made where MCI is accompanied by appropriate biomarker changes, but in practice, such biomarkers are not available in routine clinical practice in the UK. This would change if disease-modifying therapies became available and required a definitive diagnosis but would present major challenges to the National Health Service and similar health systems. Significantly increased investment would be required in training, infrastructure and provision of fluid biomarkers and neuroimaging. Statistical techniques combining markers may provide greater sensitivity and specificity than any single disease marker but their practical usefulness will depend on large-scale studies to ensure ecological validity and that multiple measures, e.g. both cognitive tests and biomarkers, are widely available for clinical use. To perform such large studies, we must increase research participation amongst those with MCI.
- 17 November 2020
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 50 (1) , 72-80
Open AccessMild Cognitive Impairment: the Manchester consensus
Given considerable variation in diagnostic and therapeutic practice, there is a need for national guidance on the use of neuroimaging, fluid biomarkers, cognitive testing, follow-up and diagnostic terminology in mild cognitive impairment (MCI). MCI is a heterogenous clinical syndrome reflecting a change in cognitive function and deficits on neuropsychological testing but relatively intact activities of daily living. MCI is a risk state for further cognitive and functional decline with 5–15% of people developing dementia per year. However, ~50% remain stable at 5 years and in a minority, symptoms resolve over time. There is considerable debate about whether MCI is a useful clinical diagnosis, or whether the use of the term prevents proper inquiry (by history, examination and investigations) into underlying causes of cognitive symptoms, which can include prodromal neurodegenerative disease, other physical or psychiatric illness, or combinations thereof. Cognitive testing, neuroimaging and fluid biomarkers can improve the sensitivity and specificity of aetiological diagnosis, with growing evidence that these may also help guide prognosis. Diagnostic criteria allow for a diagnosis of Alzheimer’s disease to be made where MCI is accompanied by appropriate biomarker changes, but in practice, such biomarkers are not available in routine clinical practice in the UK. This would change if disease-modifying therapies became available and required a definitive diagnosis but would present major challenges to the National Health Service and similar health systems. Significantly increased investment would be required in training, infrastructure and provision of fluid biomarkers and neuroimaging. Statistical techniques combining markers may provide greater sensitivity and specificity than any single disease marker but their practical usefulness will depend on large-scale studies to ensure ecological validity and that multiple measures, e.g. both cognitive tests and biomarkers, are widely available for clinical use. To perform such large studies, we must increase research participation amongst those with MCI.
- Open Access
- 3 August 2020
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 6 (5) , e81
Stigma toward mental and physical illness: attitudes of healthcare professionals, healthcare students and the general public in Pakistan
Background: The evidence base for stigma in mental health largely originates from high-income countries. Aims: This study from Pakistan aimed to address the gap in literature on stigma from low- and middle-income countries. Method: This cross-sectional study surveyed 1470 adults from Karachi, Pakistan. Participants from three groups (healthcare professionals, healthcare students and the general public) completed the adapted Bogardus Social Distance Scale (SDS) as a measure of stigma. Results: All three groups reported higher scores of stigma toward mental disorders compared with physical disorders. SDS scores for mental illness in the general public were significantly higher than in healthcare students (mean difference (MD) 6.93, 95% CI 5.45–8.45, P < 0.001) and healthcare professionals (MD 6.93, 95% CI 5.48–8.38, P < 0.001). However, SDS scores between healthcare students and healthcare professionals were not significantly different (MD 0.003, 95% CI −1.14–1.14, P > 0.99). Being female was associated with lower stigma scores and being over the age of 30 years was associated with higher stigma scores. Conclusions: Stigma campaigns in Pakistan need to target the general population. However, evidence of negative attitudes toward mental illness in healthcare students and healthcare professionals supports the need for stronger emphasis on psychiatric education within undergraduate and postgraduate training in Pakistan.
- 3 August 2020
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 6 (5) , e81
Open AccessStigma toward mental and physical illness: attitudes of healthcare professionals, healthcare students and the general public in Pakistan
Background: The evidence base for stigma in mental health largely originates from high-income countries. Aims: This study from Pakistan aimed to address the gap in literature on stigma from low- and middle-income countries. Method: This cross-sectional study surveyed 1470 adults from Karachi, Pakistan. Participants from three groups (healthcare professionals, healthcare students and the general public) completed the adapted Bogardus Social Distance Scale (SDS) as a measure of stigma. Results: All three groups reported higher scores of stigma toward mental disorders compared with physical disorders. SDS scores for mental illness in the general public were significantly higher than in healthcare students (mean difference (MD) 6.93, 95% CI 5.45–8.45, P < 0.001) and healthcare professionals (MD 6.93, 95% CI 5.48–8.38, P < 0.001). However, SDS scores between healthcare students and healthcare professionals were not significantly different (MD 0.003, 95% CI −1.14–1.14, P > 0.99). Being female was associated with lower stigma scores and being over the age of 30 years was associated with higher stigma scores. Conclusions: Stigma campaigns in Pakistan need to target the general population. However, evidence of negative attitudes toward mental illness in healthcare students and healthcare professionals supports the need for stronger emphasis on psychiatric education within undergraduate and postgraduate training in Pakistan.
- 18 June 2020
- Published by Cambridge University Press (CUP)
- p. 433-453
Drugs to Treat Dementia
Seminars in Clinical Psychopharmacology - edited by Peter M. Haddad June 2020
- 18 June 2020
- Published by Cambridge University Press (CUP)
- p. 433-453
Drugs to Treat Dementia
Seminars in Clinical Psychopharmacology - edited by Peter M. Haddad June 2020
- Open Access
- 5 March 2020
- Published by sPage.direcT in Journal of Neurodegenerative Disorders
- Vol. 3 (1)
Blueprint for a Brain Health Clinic to Detect and Manage Early-Stage Cognitive Decline: A Consensus Exercise
- 5 March 2020
- Published by sPage.direcT in Journal of Neurodegenerative Disorders
- Vol. 3 (1)
Open AccessBlueprint for a Brain Health Clinic to Detect and Manage Early-Stage Cognitive Decline: A Consensus Exercise
- 8 August 2019
- Published by Mark Allen Group in British Journal of Nursing
- Vol. 28 (15) , 1020-1025
Experiences of nurses and other health workers participating in a reflective course on compassion-based care
Background: the risk of compassion fatigue in healthcare staff is real, especially when considering the current financial pressures. A course in compassion-based care (CBC) was delivered to mental health staff at a hospital in north-west England, with the intention of rehabilitating ward culture and, subsequently, improving patient experience. Aims: to explore staff experiences of participating in the CBC course. Methods: a qualitative study using semi-structured interviews with participants (n=12) was conducted. All staff attending the course were eligible and were invited to participate. Interview transcripts were thematically analysed. Findings: five themes characterising participant experience emerged from the data: meeting a need; creating the space; reorientation; prioritising self-care; and influencing team dynamics. Data overwhelmingly indicated the success of the CBC course. Conclusion: the CBC course appeared to have a profound effect on participants; it should be considered for further rollout and evaluation.
- 8 August 2019
- Published by Mark Allen Group in British Journal of Nursing
- Vol. 28 (15) , 1020-1025
Experiences of nurses and other health workers participating in a reflective course on compassion-based care
Background: the risk of compassion fatigue in healthcare staff is real, especially when considering the current financial pressures. A course in compassion-based care (CBC) was delivered to mental health staff at a hospital in north-west England, with the intention of rehabilitating ward culture and, subsequently, improving patient experience. Aims: to explore staff experiences of participating in the CBC course. Methods: a qualitative study using semi-structured interviews with participants (n=12) was conducted. All staff attending the course were eligible and were invited to participate. Interview transcripts were thematically analysed. Findings: five themes characterising participant experience emerged from the data: meeting a need; creating the space; reorientation; prioritising self-care; and influencing team dynamics. Data overwhelmingly indicated the success of the CBC course. Conclusion: the CBC course appeared to have a profound effect on participants; it should be considered for further rollout and evaluation.